NeuroSense Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Current Ratio Growth & History (NRSN)
NeuroSense Therapeutics's current ratio was 0.31 for fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.31 | −1.90 | −86.01% |
| 2024 | 2024-12-31 | 2.21 | 1.37 | +162.13% |
| 2023 | 2023-12-31 | 0.84 | −3.43 | −80.29% |
| 2022 | 2022-12-31 | 4.28 | −14.84 | −77.63% |
| 2021 | 2021-12-31 | 19.12 | 12.73 | +199.46% |
| 2020 | 2020-12-31 | 6.38 | — | — |
NeuroSense Therapeutics quarterly current ratio
Q4.20
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.31 | −1.90 | −86.01% |
| Q2 2025 | 2025-06-30 | 0.71 | 0.24 | +53.04% |
| Q4 2024 | 2024-12-31 | 2.21 | 1.37 | +162.13% |
| Q2 2024 | 2024-06-30 | 0.46 | −2.05 | −81.66% |
| Q4 2023 | 2023-12-31 | 0.84 | −3.43 | −80.29% |
| Q2 2023 | 2023-06-30 | 2.52 | −12.57 | −83.32% |
| Q4 2022 | 2022-12-31 | 4.28 | −14.84 | −77.63% |
| Q2 2022 | 2022-06-30 | 15.09 | — | — |
| Q4 2021 | 2021-12-31 | 19.12 | 12.73 | +199.46% |
| Q4 2020 | 2020-12-31 | 6.38 | — | — |
NeuroSense Therapeutics current ratio trends
Over the last five fiscal years, NeuroSense Therapeutics's current ratio decreased from 6.38 to 0.31, a change of −6.07. The latest reported quarter, Q4 2025, shows 0.31.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics source filings ↗